RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.
Possibly more cases of gastroenteritis caused by antacids In recent years the Netherlands has witnessed an increase in the number of cases of gastroenteritis caused by the Campylobacter bacterium.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Teenage girl dies after measles infection Last weekend, a 17-year-old girl from the province of Zeeland (The Netherlands) has died of complications after a measles infection. She was not vaccinated against the disease.
Extra measles vaccinations for risk groups Some areas of the Netherlands where families for religious reasons chose not to get their babies vaccinated are now reporting cases of measles, and it is expected that the number of cases will incr
Fewer municipalities with low vaccination coverage In the Netherlands, there are 80 municipalities with a low vaccination coverage for one or more vaccinations. This is a decrease compared to last year when there were still 90 municipalities.
Regulation of nanomaterials needs more than definition alone In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.